Tests Airsupra started in the emergency department for acute asthma
Tests whether starting Airsupra in the emergency room helps adults with acute asthma.
Plain-language title generated from the registry record
Registry title: 45th Multicenter Airway Research Collaboration
Key facts
- Where
- Cleveland, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 54 years old?
Source: NCT07166939, who can take part
Where in United States
- MetroHealthCleveland, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT07166939
- Record updated
- 17 April 2026
- Original description
The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma "recurrence" at 3 months and other related outcomes (acute asthma relapse, asthma control).Read full original descriptionShow less
A Phase 4, Multicenter, Cluster Randomized, Open-label, Intervention Versus Usual Care, Controlled Study on the Effect of Emergency Department Initiation of Airsupra on Asthma Outcomes
The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma "recurrence" at 3 months and other related outcomes (acute asthma relapse, asthma control).
Inclusion: acute asthma; age 18.0 to 54.9 years; English and/or Spanish speaking; decision by ED attending to discharge patient to home on short course of systemic corticosteroids; (intervention group only) Willingness to use Airsupra as their rescue inhaler for next 3 months; demonstration of acceptable MDI administration technique; provision of informed consent prior to any study-specific procedures.
Exclusion: previous enrolment in the present study; prior diagnosis of COPD, chronic bronchitis, or emphysema; use of systemic corticosteroids in the past 2 weeks; participation in another clinical study with an investigational product during the past 4 weeks or the 3 months after enrollment in the current study; concurrent pneumonia; clinically significant cardiovascular disease or clinically significant cancer; patients with known hypersensitivity to Airsupra, albuterol sulfate, budesonide, or any of the excipients of the product; (among sexually active women of child-bearing age only) not using adequate contraception over the last 3 months, or no plan to use adequate contraception over the next 3 months; involvement in the planning and/or conduct of the study; (for women only, by self-report):; currently pregnant; currently breastfeeding,; lack of a working cell phone and working email address; expected lack of availability for text and/or telephone follow-up at approximately 3, 6, and 12 weeks after the ED visit; inability to provide an alternate contact with a working cell phone and working email address.